CD4 and cancer: Cancer patients with high levels of CXCL16 expression have shown more elevated levels of CD4(+) and CD8(+) tumor-infiltrating lymphocytes and NK, leading to improved disease prognosis (Hojo et al., 2007; Valdivia-Silva et al., 2015).